364 related articles for article (PubMed ID: 31694630)
1. Vertebral bone marrow fat fraction changes in postmenopausal women with breast cancer receiving combined aromatase inhibitor and bisphosphonate therapy.
Dieckmeyer M; Ruschke S; Rohrmeier A; Syväri J; Einspieler I; Seifert-Klauss V; Schmidmayr M; Metz S; Kirschke JS; Rummeny EJ; Zimmer C; Karampinos DC; Baum T
BMC Musculoskelet Disord; 2019 Nov; 20(1):515. PubMed ID: 31694630
[TBL] [Abstract][Full Text] [Related]
2. Changes in Vertebral Marrow Fat Fraction Using 3D Fat Analysis & Calculation Technique Imaging Sequence in Aromatase Inhibitor-Treated Breast Cancer Women.
Wan T; Zhu Y; Han Q; Liu L
Front Endocrinol (Lausanne); 2022; 13():931231. PubMed ID: 35813643
[TBL] [Abstract][Full Text] [Related]
3. Texture analysis of vertebral bone marrow using chemical shift encoding-based water-fat MRI: a feasibility study.
Burian E; Subburaj K; Mookiah MRK; Rohrmeier A; Hedderich DM; Dieckmeyer M; Diefenbach MN; Ruschke S; Rummeny EJ; Zimmer C; Kirschke JS; Karampinos DC; Baum T
Osteoporos Int; 2019 Jun; 30(6):1265-1274. PubMed ID: 30903208
[TBL] [Abstract][Full Text] [Related]
4. TBS and BMD at the end of AI-therapy: A prospective study of the B-ABLE cohort.
María RS; Marta PM; Sonia S; Natalia GG; Tamara M; Ignasi T; Maria MG; Jaime RM; Adolfo DP; Joan A; Xavier N
Bone; 2016 Nov; 92():1-8. PubMed ID: 27519968
[TBL] [Abstract][Full Text] [Related]
5. Chemical Shift-Encoded MRI of the Lumbar Vertebral Bone Marrow for Detecting Osteoporosis With Low Trabecular Bone Quality in Patients With Breast Cancer Receiving Aromatase Inhibitors.
Misaka T; Hashimoto Y; Ashikaga R; Ishida T
J Magn Reson Imaging; 2024 Jan; ():. PubMed ID: 38174771
[TBL] [Abstract][Full Text] [Related]
6. Texture Analysis Using CT and Chemical Shift Encoding-Based Water-Fat MRI Can Improve Differentiation Between Patients With and Without Osteoporotic Vertebral Fractures.
Sollmann N; Becherucci EA; Boehm C; Husseini ME; Ruschke S; Burian E; Kirschke JS; Link TM; Subburaj K; Karampinos DC; Krug R; Baum T; Dieckmeyer M
Front Endocrinol (Lausanne); 2021; 12():778537. PubMed ID: 35058878
[TBL] [Abstract][Full Text] [Related]
7. Associations of incidental vertebral fractures and longitudinal changes of MR-based proton density fat fraction and T2* measurements of vertebral bone marrow.
Leonhardt Y; Ketschau J; Ruschke S; Gassert FT; Glanz L; Feuerriegel GC; Gassert FG; Baum T; Kirschke JS; Braren RF; Schwaiger BJ; Makowski MR; Karampinos DC; Gersing AS
Front Endocrinol (Lausanne); 2022; 13():1046547. PubMed ID: 36465625
[TBL] [Abstract][Full Text] [Related]
8. Vertebral Bone Marrow Heterogeneity Using Texture Analysis of Chemical Shift Encoding-Based MRI: Variations in Age, Sex, and Anatomical Location.
Dieckmeyer M; Junker D; Ruschke S; Mookiah MRK; Subburaj K; Burian E; Sollmann N; Kirschke JS; Karampinos DC; Baum T
Front Endocrinol (Lausanne); 2020; 11():555931. PubMed ID: 33178134
[No Abstract] [Full Text] [Related]
9. Measurement of vertebral bone marrow proton density fat fraction in children using quantitative water-fat MRI.
Ruschke S; Pokorney A; Baum T; Eggers H; Miller JH; Hu HH; Karampinos DC
MAGMA; 2017 Oct; 30(5):449-460. PubMed ID: 28382554
[TBL] [Abstract][Full Text] [Related]
10. Aromatase inhibitor-induced bone mineral loss and its prevention by bisphosphonate administration in postmenopausal breast cancer patients.
Yonehara Y; Iwamoto I; Kosha S; Rai Y; Sagara Y; Douchi T
J Obstet Gynaecol Res; 2007 Oct; 33(5):696-9. PubMed ID: 17845332
[TBL] [Abstract][Full Text] [Related]
11. Long-term effect of aromatase inhibitors on bone microarchitecture and macroarchitecture in non-osteoporotic postmenopausal women with breast cancer.
Hong AR; Kim JH; Lee KH; Kim TY; Im SA; Kim TY; Moon HG; Han WS; Noh DY; Kim SW; Shin CS
Osteoporos Int; 2017 Apr; 28(4):1413-1422. PubMed ID: 28083668
[TBL] [Abstract][Full Text] [Related]
12. Longitudinal changes in bone mineral density and trabecular bone score following yearly zoledronic acid infusion in postmenopausal osteoporosis-a retrospective-prospective study from southern India.
Sooragonda B; Cherian KE; Jebasingh FK; Dasgupta R; Asha HS; Kapoor N; Thomas N; Paul TV
Arch Osteoporos; 2019 Jul; 14(1):79. PubMed ID: 31321603
[TBL] [Abstract][Full Text] [Related]
13. Effect of denosumab on low bone mineral density in postmenopausal Japanese women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: 24-month results.
Nakatsukasa K; Koyama H; Ouchi Y; Ono H; Sakaguchi K; Matsuda T; Kato M; Ishikawa T; Yamada K; Yoshimura M; Koizumi K; Sakurai T; Shigematsu H; Takahashi S; Taira S; Suzuki M; Narui K; Niikura N; Hasegawa Y; Miura D; Konishi E; Taguchi T;
Breast Cancer; 2019 Jan; 26(1):106-112. PubMed ID: 30054855
[TBL] [Abstract][Full Text] [Related]
14. Associations of gestational diabetes and proton density fat fraction of vertebral bone marrow and paraspinal musculature in premenopausal women.
Harada S; Gersing AS; Stohldreier Y; Dietrich O; Lechner A; Seissler J; Ferrari U; Pappa E; Hesse N
Front Endocrinol (Lausanne); 2023; 14():1303126. PubMed ID: 38292769
[TBL] [Abstract][Full Text] [Related]
15. Bone Marrow Adiposity and Fragility Fractures in Postmenopausal Women: The ADIMOS Case-Control Study.
Paccou J; Badr S; Lombardo D; Khizindar H; Deken V; Ruschke S; Karampinos DC; Cotten A; Cortet B
J Clin Endocrinol Metab; 2023 Sep; 108(10):2526-2536. PubMed ID: 37017011
[TBL] [Abstract][Full Text] [Related]
16. MR-based proton density fat fraction (PDFF) of the vertebral bone marrow differentiates between patients with and without osteoporotic vertebral fractures.
Gassert FT; Kufner A; Gassert FG; Leonhardt Y; Kronthaler S; Schwaiger BJ; Boehm C; Makowski MR; Kirschke JS; Baum T; Karampinos DC; Gersing AS
Osteoporos Int; 2022 Feb; 33(2):487-496. PubMed ID: 34537863
[TBL] [Abstract][Full Text] [Related]
17. Effects of zoledronic acid on bone mineral density during aromatase inhibitor treatment of Korean postmenopausal breast cancer patients.
Lee SA; Hwang SH; Ahn SG; Lee HM; Jeong J; Lee HD
Breast Cancer Res Treat; 2011 Dec; 130(3):863-70. PubMed ID: 21861101
[TBL] [Abstract][Full Text] [Related]
18. Changes in bone mineral density in women with breast cancer receiving aromatase inhibitor therapy.
Kwan ML; Yao S; Laurent CA; Roh JM; Quesenberry CP; Kushi LH; Lo JC
Breast Cancer Res Treat; 2018 Apr; 168(2):523-530. PubMed ID: 29249058
[TBL] [Abstract][Full Text] [Related]
19. Bisphosphonates may protect against bone loss in postmenopausal women with early breast cancer receiving adjuvant aromatase inhibitor therapy: results from a meta-analysis.
Su G; Xiang Y; He G; Jiang C; Li C; Yan Z; Zhong Y
Arch Med Res; 2014 Oct; 45(7):570-9. PubMed ID: 25450582
[TBL] [Abstract][Full Text] [Related]
20. Predictive factors for the efficacy of denosumab in postmenopausal Japanese women with non-metastatic breast cancer receiving adjuvant aromatase inhibitors: a combined analysis of two prospective clinical trials.
Nakatsukasa K; Koyama H; Ouchi Y; Sakaguchi K; Fujita Y; Matsuda T; Kato M; Konishi E; Taguchi T
J Bone Miner Metab; 2019 Sep; 37(5):864-870. PubMed ID: 30868270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
